Hội đồng quản trị Tài Cực Group đã thông qua nhiều dự thảo nghị quyết hàng năm, dự kiến không phân phối lợi nhuận và gia hạn hợp đồng kiểm toán.

中访网数据 重庆太极实业（集团）股份有限公司于2026年3月25日召开了第十届董事会第三十七次会议，审议通过了多项重要年度议案。
Core decision includes: The company intends not to distribute profits for the fiscal year 2025, meaning no cash dividends, no stock issuance, and no capital reserve transfer to increase share capital, primarily to ensure funding for production operations and capacity construction in 2026.
财务数据显示，公司2025年度归属于上市公司股东的净利润为1.21亿元，年末可供投资者分配的利润为8.24亿元。
The meeting also approved the “2025 Annual Report and Summary,” and reviewed matters related to impairment provision, 2026 financial budget, etc.
为满足经营需要，董事会同意公司申请2026年度综合授信额度，该议案尚需提交股东大会审议。
In terms of related party transactions, the board approved the proposal to re-sign the “Financial Service Agreement” with China National Pharmaceutical Group Finance Co., Ltd., and related directors abstained from voting.
此外，董事会决议续聘立信会计师事务所为公司2026年度财务报告和内部控制审计机构。
The meeting also approved the technical transformation project of the preprocessing workshop in the Dongzikou plant of the wholly-owned subsidiary Taiji Group Chongqing Traditional Chinese Medicine No. 2 Factory, as well as a budget of 2.26 million yuan for external donations in 2026.
为优化资产结构，公司计划对外公开转让所持重庆市金科商业保理有限公司和重庆市金科金融保理有限公司的股权。
上述涉及利润分配、综合授信、关联交易及续聘审计机构等多项议案将提交公司2025年年度股东大会审议。

海量资讯、精准解读，尽在新浪财经APP